National
General says open service would be problematic
A retired general who supports “Don’t Ask, Don’t Tell” raised eyebrows last week when he said open service in a foreign military led to a horrific massacre and suggested lifting the U.S. ban would lead to sexual assault.
During a hearing March 18 before the Senate Armed Services Committee, Gen. John Sheehan, a former commander for U.S. Atlantic Command, said lifting the ban on open service in the Netherlands contributed to the country’s inability to prevent the Srebrenica massacre in 1995.
The event, in which the Serbian military executed more than 8,000 Bosniak men and boys, occurred after a United Nations protection force of around 400 Dutch peacekeepers failed to stop the massacre.
Sheehan, who retired from the U.S. military 13 years ago, identified this event as a product of the how the Dutch — as well as other militaries throughout Europe — dropped their bans to include “open homosexuality” as part of the liberalization of these armed forces following the collapse of the Soviet Union.
“They declared a peace dividend and made a conscious effort to socialize their military,” he said. “They did not believe the Germans were going to attack again or the Soviets were coming back. That led to force that was ill-equipped to go to war.”
Sheehan said he heard from a former Dutch military leader that the Srebrenica killings were the result of the liberalization of the armed forces, which he called an effect of “social engineering.”
But Senate Armed Services Committee Chairman Carl Levin (D-Mich.) rebuked the notion that the massacre was the result of allowing gays to serve openly in the Dutch military.
“Any effort to connect that failure on the part of the Dutch to the fact that they have homosexuals or did allow homosexuals, I think, is totally off target,” he said. “I’ve seen no suggestion of that.”
Levin said the failures of Srebrenica were the result of Dutch troops being trained as peacekeepers and not what was required to conduct the mission.
In a statement provided by Levin, Dutch Ambassador to the United States Renée Jones-Bos said he “couldn’t disagree more” with Sheehan’s comments and that he takes pride in how lesbians and gays are allowed to serve openly in the Dutch military.
“The military mission of Dutch U.N. soldiers at Srebrenica has been exhaustively studied and evaluated, nationally and internationally,” he said. “There is nothing in these reports that suggests any relationship between gays serving in the military and the mass murder of Bosnian Muslims.”
Sheehan also expressed concern that open service would lead to sexual assault in the military, as well as other problems should gay service members engage in inappropriate contact with other troops.
Recalling his days in the Vietnam War, Sheehan said there was incident in which a young Marine was being molested by his sergeant in a foxhole. Sheehan noted that the two fought, and a machine gun section near the foxhole opened up and almost killed a combat patrol.
When the young Marine reported this incident, Sheehan said there was a disruption in unit cohesion because the sergeant denied molesting the young Marine and many didn’t believe the allegations.
“For about three days, that unit divided down the middle,” Sheehan said. “Those that supported the popular squad leader, [and] those that kind of thought the new kid might be believable.”
An end to divisiveness came, Sheehan said, when the sergeant committed the same offense three days later.
“But the real tragedy of this story is the young [private] continually insisted for a long period of time that nobody in his organization believed that it happened,” he said. “He lost faith in his chain of command.”
To further his case about concerns on sexual assault, Sheehan also cited a report from the Defense Department last year noting a net increase of 3,200 sexual assaults in the military. He said 7 percent of these incidents — or about 226 — were male-on-male assaults.
“I would stipulate that from my days in Vietnam in the early 60s, when I had this sergeant that almost got a combat patrol killed, to the 226 male soldiers and Marines who were molested, that there’s something wrong with our sexual behavior policy,” he said.
Sen. Joseph Lieberman (I-Conn.), the sponsor of “Don’t Ask, Don’t Tell” repeal legislation in the Senate, said he didn’t share the view that open service would lead to sexual assaults in the military.
“The episode you gave of the sexual assault, Gen. Sheehan, with one man assaulting another man, could, of course, easily and unfortunately does happen more with a man assaulting a women in uniform,” he said.
Lieberman noted statistics Sheehan gave of 7 percent of assaults being male-on-male means 93 percent are heterosexual assault.
“I know there may be fears that if we repeal ‘Don’t Ask, Don’t Tell,’ there’ll be behavior inconsistent with good order and discipline, including sexual assault,” Lieberman said. “But if that happens, they’ll be held to the same account and discipline.”
Two witnesses who testified in favor of repealing “Don’t Ask, Don’t Tell” were Michael Almy, a gay former Air Force communications officer, and Jenny Kopfstein, a lesbian former Navy surface warfare officer. Almy was discharged from service under the ban in 2006 and Kopfstein was discharged in 2002.
Sen. John McCain (R-Ariz) asked both Almy and Kopfstein whether they favored a “thorough, complete” review of “Don’t Ask, Don’t Tell,” as is currently underway in the Pentagon.
Kopfstein said she didn’t have a problem with the review, but that it’s clear the law should be changed.
Almy, however, said he doesn’t favor the study because other changes have taken place in the military without such work.
“We have not done this on any other issues with regard to change to the military — as far as, most recently, putting women in submarines, women in the service academies,” he said. “We did not survey the forces then on those issues. The military is not a democracy. I don’t see this issue as any different, senator.”
McCain said he was “confused about” the opposition to conducting the Pentagon study as means to find out whether “Don’t Ask, Don’t Tell” should be repealed.
“I will continue to argue and fight for whatever I can to make sure that we have a thorough, objective review of the impact on the military of the change of this law,” McCain said. “I think the men and women who serving in the military deserve no less.”
A number of committee members during the hearing expressed their personal viewpoints on “Don’t Ask, Don’t Tell.” Sen. Jim Webb (D-Va.), who’s seen as a swing vote on repeal this year, emphasized the importance of waiting for the completion of the Pentagon review before taking action.
“I don’t want to predict at all where this is going to go,” he said. “I just think that it is vital that we can say to the people in the military and the American people that we’ve been responsible in terms of how a decision has been made.”
But Sen. Roland Burris (D-Ill.) said that in response to the stories of people who are being expelled under “Don’t Ask, Don’t Tell,” a moratorium should be placed on the law’s enforcement to prevent further discharges.
“I think that we need to put a moratorium on this situation right now — don’t let anyone be discharged from the military because of their sexual orientation until we can change this law,” he said.
Following the hearing, Servicemembers Legal Defense Network Executive Director Aubrey Sarvis said the hearing showed “a stark, realistic division” between young service members and retired members of the military from Sheehan’s generation.
“By and large, today’s warriors are fine with gays and lesbian serving openly,” he said. “Obviously, Gen. Sheehan, like some of the joint chiefs, are expressing resistance, dragging their feet.”
But Sarvis said the process that’s underway is examining how to bring about open service in the military “in a smooth, orderly way.”
“That’s what this debate should be about — it should be how,” he said. “It’s not if, it’s not whether, it’s about how we bring about this change.”
Last week’s Senate Armed Services Committee hearing occurred alongside other events that brought attention to “Don’t Ask, Don’t Tell,” including Servicemembers Legal Defense Network’s lobby day on Capitol Hill; the Human Rights Campaign’s rally on Freedom Plaza; and an act of civil disobedience by gay U.S. Army Lt. Dan Choi, who handcuffed himself to the White House gates in protest of the law.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
